DC
KYTX icon

Diametric Capital’s Kyverna Therapeutics KYTX Stock Holding History

Diametric Capital’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,067
Closed -$139K – 715
2026
Q1 		$139K Buy
+16,067
New +$134K 0.04% 405
2024
Q2 		– Sell
-9,300
Closed -$231K – 485
2024
Q1 		$231K Buy
+9,300
New +$259K 0.13% 221

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Diametric Capital's KYTX Position: Q2 2026 in Review

Diametric Capital sold out of Kyverna Therapeutics (KYTX) in Q2 2026, closing a stake of 16,067 shares — an estimated $139K sold.

Diametric Capital first reported a position in KYTX in Q1 2024 and held it in 2 quarters. The position peaked at $231K in Q1 2024. 121 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Diametric Capital reported no remaining Kyverna Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Diametric Capital sold 16,067 Kyverna Therapeutics shares in Q2 2026, an estimated $139K.
  • Diametric Capital first reported a position in Kyverna Therapeutics in Q1 2024 and held it in 2 quarters.
  • Diametric Capital's Kyverna Therapeutics position peaked at $231K in Q1 2024.
  • 121 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Diametric Capital's 13F filing for Q2 2026, filed 14 Aug 2026.